Search

"Evidence suggests a hormone peptide named adropin, is involved in lipid metabolism, insulin resistance, and obesity. However, its role in pathogenesis of type 2 diabetes mellitus (T2DM) is still unclear in humans. Therefore, we investigated whether adropin levels are altered in T2DM patients, and evaluated its association with diabetes- related parameters. Men with T2DM (n=40) and age-matched healthy men (n=40) were participated in case-control study. Serum adropin levels were determined by ELISA. Adropin levels were found to be significantly (p=0.004) higher in T2DM patients (median=2.5ng/ml; interquartile range=1.28ng/ml) compared to healthy controls (Median=1.9ng/ml; interquartile range =0.6ng/ml). Adropin was inversely correlated with FBG (Spearman's rho= -0.335; p=0.017) in T2DM patients and was also negatively correlated with HOMA-IR (Spearman's rho= -0.391; p=0.024). Adropin i‚³ 2.25 ng/ml was the best cut-off point to differentiate T2DM patients from healthy controls (sensitivity= 57.5%; specificity= 82.5%; positive predictive value=76.67%; negative predictive value=66%). We showed that T2DM patients have higher adropin levels, and serum level of adropin is inversely associated with insulin resistance; therefore indicating a close association between adropin and T2DM. However, further studies are necessary to establish the role of adropin in diabetes."

Aim and Background: In patients with type 2 diabetes mellitus complicated with renal failure achieving good glucose control and reduction of risk of hypoglycemia should be balanced. The aim of this study was to determine the safety and efficacy of insulin glargine in type 2 diabetic patients with diabetic nephropathy. Methods: A total of 89 subjects with type 2 diabetes (mean age 62.9 ± 10.7 and diabetes duration 13.9 ± 7.6 years) who had diabetic nephropathy (mean Glomerular FiltrationR [GFR] 34.1 ± 11.5 ml/min) were included in the study. Patients who were not optimally controlled or experienced frequent hypoglycemia on Oral Antidiabetic Drugs (OAD) or NPH insulin received insulin glargine at bedtime. The starting dose was 0.1 unit /Kg and adjusted to obtain target fasting blood glucose (5-7.2 mmol/l). The medical records were obtained before and 2 and 4 months after beginning insulin glargine. Results: At the end of four month treatment period, significant reduction in glycated hemoglobin (HbA 1 c) was observed (from 8.4% ± 1.6 to 7.7% ± 1.2) (p

Introduction : Studies have shown altered protein metabolism in the presence of excess carbohydrate such as type 2 diabetes (T2DM). Protein metabolism is impaired in T2DM as a result of oxidative stress and insulin resistance. Here we aimed to study the correlation of serum urea as an indicator of protein metabolism with malondialdehyde (MDA) and superoxide dismutase (SOD), as indicators of oxidative stress in T2DM patients. Methods : We performed a cross sectional study on 151 patients with T2DM and 45 healthy controls. We quantified fasting blood sugar (FBS), HbA1C, lipid profile, urea, MDA and SOD in the studied groups. Results : Patients had a higher serum urea, FBS, HbA1C, triglyceride, cholesterol, LDL, MDA and SOD than controls. GFR and serum HDL levels were lower in patients. Diabetic men had a lower HDL and a higher albuminuria compared to diabetic women. There were no difference in any of the studied variables between men and women in control group. Serum urea levels were negatively correlated with MDA (r= -0.70, p

Introduction: Screening silent myocardial ischemia in asymptomatic patients with type 2 diabetes is still controversial. The purpose of the present study was to define the value of diabetic foot ulcer (DFU) in the prediction of silent myocardial ischemia in asymptomatic men and women with type 2 diabetes. Methods: We performed a cross sectional study on 150 diabetic patients with DFU, as cases, and 90 diabetic patients, without the history of any type of DFU, as controls. Presence of silent myocardial ischemia was assessed by dipyridamole single-photon emission- computed tomography myocardial perfusion (SPECT) imaging with thallium-201. Results: Patients with DFU had longer diabetes duration, higher serum HbA1C, and lower serum high density lipoprotein cholesterol levels, compared to patients without DFU. There were a greater number of women with silent myocardial ischemia (28/63 (44.4%) vs. 28/87 (32.2%); p